This book provides a comprehensive and up-to-date overview of all the upper and lower airways disorders and broadens their understanding by combining ENT and pulmonology disciplines. The volume opens with a general overview on the airways, before describing symptoms, infections and allergies. In addition to the upper airway tumors, specific lower, and upper airway disorders, other topics addressed by the book are pediatric lower airway disorders, sleep related breathing disorders, trauma, reflux, and interventional pulmonology. The closing part discusses the airway protection and includes a chapter on gender and pulmonary diseases. Written by experts in the fields, the book is a valuable resource for both specialists and trainees in ENT, pulmonology, and pediatrics.

The book explores the intersection of nanotechnology and allergic airway diseases. With a focus on diagnosis and management, each chapter delves into specific areas of interest. Beginning with an introduction to the diseases, the book progresses to uncover the pathophysiology and immunology underlying allergic airway diseases. The epidemiology chapter provides insights into the prevalence and impact of these conditions. A significant portion of the book is dedicated to nanotechnology applications, with chapters on metal and metal oxide nanoparticles, nanomicelles, carbon nanotubes, liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, nanofibers, and quantum dots. These chapters delve into the potential of these nanomaterials in managing allergic airway diseases, highlighting their unique properties, and promising therapeutic approaches. Finally, the book concludes with a chapter on future directions, exploring emerging trends and potential advancements in the field. This book will be a valuable resource for academics, caregivers, researchers, and industry professionals working in the field of airway allergic diseases. It includes translational and clinical researchers, under-graduates and postgraduates (Masters), PhDs, and post-doctoral researchers of various disciplines, including pharmaceutical sciences, biotechnology, immunology, and medical and health sciences.

In this issue of Otolaryngologic Clinics, guest editors Drs. Devyani Lal, Angela Donaldson, and David Jang bring their considerable expertise to the topic of Unified Airway Disease. Unified airway disease is a recently defined entity that alludes to inflammation disease processes that involve both upper and lower airway, and co-management of these conditions by otolaryngologists and allergy immunologists often result in improved outcomes. In this issue, experts in the field provide a thorough overview of the pathophysiology, diagnosis, and management of unified airway disease through the perspective of an otolaryngologist co-managing the patient with an allergy-immunology colleague. - Contains 16 practice-oriented topics including environmental factors; eosinophilic disease; non-eosinophilic and granulomatous disease; cystic fibrosis; pediatric unified airway disease; unified airway disease medical and surgical management; future directions; and more. - Provides in-depth clinical reviews on unified airway disease, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is imperative that research be undertaken to discover new treatment options. Obstructive Airway Diseases: Role of Lipid Mediators discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states. Topics discussed include: Obstructive airway diseases, etiology, pathophysiology, and existing therapeutic options What constitutes a lipid and how it is broken down to generate biologically active mediators The role of enzymes in the process of lipid mediator synthesis The biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid and the role they play in airway inflammation Products of arachidonic acid metabolism such as leukotrienes, prostaglandins, epieicosatrienoic acid, and oxoeicosatetraenoic acid Proresolution lipid mediators in inflammatory airway disease conditions The role of sphingosine and ceramide in inflammatory airway disease Protein kinases activated by lipid mediators and those that trigger the generation of lipid messengers The combined input of a panel of international authorities on lipid mediators makes this volume a valuable resource for all those involved in researching, teaching, and studying airway inflammation as well as those involved in drug discovery research. Punit Srivastava maintains a blog with additional information about the book and his work.

This clinical reference for practitioners offers a new and comprehensive look at chronic obstructive lung disease. Global in scale and importance, it is an important cause of morbidity and mortality. Bringing together a roster of internationally renowned contributors from the front lines of pulmonary medicine and research, it is aimed at practitioners in pulmonary medicine, pathology, thoracic radiology and epidemiology. Its focus is on the pathobiology of chronic obstructive pathology disease and emphysema and its exacerbation of chronic obstructive pulmonary disease and on treatment options. This reference works to 'connect the dots' by collating and centralizing the various data on the subject.

This comprehensive text expounds the pathophysiology, diagnosis, and treatment of lung disease associated with rheumatoid arthritis (RA), an autoimmune disease that primarily affects joints. Recent advances in therapy for RA provide the benefit of achieving a better outcome in patients with arthritis, and a large number of reports on RA are now available. Moreover, the American College of Rheumatology and the European League Against Rheumatism have proposed guidelines and recommendations for management of RA patients. Therefore, clinicians around the world can adequately understand how to manage patients who have joint symptoms in RA. At the same time, however, the management of RA patients who have lung problems has not been disseminated sufficiently, although lung disease is a common complication in approximately 30–40 % of patients with RA. Unfortunately, there has been a lack of tangible evidence regarding the pathophysiology, diagnosis, and management of lung disease associated with RA. Each expert author in this book elucidates the current status of knowledge about lung disease in RA and the management of RA patients with lung diseases. Thus this valuable collection benefits not only rheumatologists but also respirologists, radiologists, pathologists, general practitioners, and medical staff such as nurses who are involved in the management of RA.

Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease provides a comprehensive, clinically focused textbook on rare and so-called ‘orphan’ pulmonary diseases. The book is oriented towards the diagnostic approach, including manifestations suggesting the disease, diagnostic criteria, methods of diagnostic confirmation, and differential diagnosis, with an overview of management.

This book has been replaced by "Rare Diseases of the Respiratory System", ISBN 978-1-84984-167-2 A respiratory physician is only likely to see a few orphan lung diseases each year or even during their career. However, it is essential that specialists are able identify, confirm and diagnosis orphan lung disease in a patient. This Monograph comprehensively covers the most common and/or complex orphan lung diseases. It should be seen as a solid companion to the respiratory specialist each time they need to consider a diagnosis of an orphan disease.